Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

Aurelio Cafaro, Antonella Caputo, Claudio Fracasso, Maria T. Maggiorella, Delia Goletti, Silvia Baroncelli, Monica Pace, Leonardo Sernicola, Martin L. Koanga-Mogtomo, Monica Betti, Alessandra Borsetti, Roberto Belli, Lennart Åkerblom, Franco Corrias, Stefano Buttò, Jonathan Heeney, Paola Verani, Fausto Titti, Barbara Ensoli

Research output: Contribution to journalArticle

Abstract

Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4+ T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.

Original languageEnglish
Pages (from-to)643-650
Number of pages8
JournalNature Medicine
Volume5
Issue number6
DOIs
Publication statusPublished - Jun 1999

Fingerprint

tat Gene Products
Simian Immunodeficiency Virus
Macaca fascicularis
Virus Diseases
Viruses
Vaccines
HIV
AIDS Vaccines
Virus Internalization
Cellular Immunity
HIV-1
Vaccination
T-Lymphocytes
Infection
T-cells
human immunodeficiency virus type 1 Tat vaccine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cafaro, A., Caputo, A., Fracasso, C., Maggiorella, M. T., Goletti, D., Baroncelli, S., ... Ensoli, B. (1999). Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature Medicine, 5(6), 643-650. https://doi.org/10.1038/9488

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. / Cafaro, Aurelio; Caputo, Antonella; Fracasso, Claudio; Maggiorella, Maria T.; Goletti, Delia; Baroncelli, Silvia; Pace, Monica; Sernicola, Leonardo; Koanga-Mogtomo, Martin L.; Betti, Monica; Borsetti, Alessandra; Belli, Roberto; Åkerblom, Lennart; Corrias, Franco; Buttò, Stefano; Heeney, Jonathan; Verani, Paola; Titti, Fausto; Ensoli, Barbara.

In: Nature Medicine, Vol. 5, No. 6, 06.1999, p. 643-650.

Research output: Contribution to journalArticle

Cafaro, A, Caputo, A, Fracasso, C, Maggiorella, MT, Goletti, D, Baroncelli, S, Pace, M, Sernicola, L, Koanga-Mogtomo, ML, Betti, M, Borsetti, A, Belli, R, Åkerblom, L, Corrias, F, Buttò, S, Heeney, J, Verani, P, Titti, F & Ensoli, B 1999, 'Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine', Nature Medicine, vol. 5, no. 6, pp. 643-650. https://doi.org/10.1038/9488
Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature Medicine. 1999 Jun;5(6):643-650. https://doi.org/10.1038/9488
Cafaro, Aurelio ; Caputo, Antonella ; Fracasso, Claudio ; Maggiorella, Maria T. ; Goletti, Delia ; Baroncelli, Silvia ; Pace, Monica ; Sernicola, Leonardo ; Koanga-Mogtomo, Martin L. ; Betti, Monica ; Borsetti, Alessandra ; Belli, Roberto ; Åkerblom, Lennart ; Corrias, Franco ; Buttò, Stefano ; Heeney, Jonathan ; Verani, Paola ; Titti, Fausto ; Ensoli, Barbara. / Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. In: Nature Medicine. 1999 ; Vol. 5, No. 6. pp. 643-650.
@article{23aab3c65e07452091e3f30bbaac8563,
title = "Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine",
abstract = "Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4+ T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.",
author = "Aurelio Cafaro and Antonella Caputo and Claudio Fracasso and Maggiorella, {Maria T.} and Delia Goletti and Silvia Baroncelli and Monica Pace and Leonardo Sernicola and Koanga-Mogtomo, {Martin L.} and Monica Betti and Alessandra Borsetti and Roberto Belli and Lennart {\AA}kerblom and Franco Corrias and Stefano Butt{\`o} and Jonathan Heeney and Paola Verani and Fausto Titti and Barbara Ensoli",
year = "1999",
month = "6",
doi = "10.1038/9488",
language = "English",
volume = "5",
pages = "643--650",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

AU - Cafaro, Aurelio

AU - Caputo, Antonella

AU - Fracasso, Claudio

AU - Maggiorella, Maria T.

AU - Goletti, Delia

AU - Baroncelli, Silvia

AU - Pace, Monica

AU - Sernicola, Leonardo

AU - Koanga-Mogtomo, Martin L.

AU - Betti, Monica

AU - Borsetti, Alessandra

AU - Belli, Roberto

AU - Åkerblom, Lennart

AU - Corrias, Franco

AU - Buttò, Stefano

AU - Heeney, Jonathan

AU - Verani, Paola

AU - Titti, Fausto

AU - Ensoli, Barbara

PY - 1999/6

Y1 - 1999/6

N2 - Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4+ T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.

AB - Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4+ T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0033026062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033026062&partnerID=8YFLogxK

U2 - 10.1038/9488

DO - 10.1038/9488

M3 - Article

C2 - 10371502

AN - SCOPUS:0033026062

VL - 5

SP - 643

EP - 650

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 6

ER -